Article successfully added.

CyFlow™ CD79a Purified

CyFlow™ CD79a Purified
Alternative Name: IgA , MB-1, MB1
Antibody: Yes
Antigen: CD79a
Application: Flow cytometry, Immunohistochmistry (paraffin-embedded sections), Immunoprecipitation, Western blot
Clonality: monoclonal
Clone: HM47
Field of Interest: Immunophenotyping
Format/Fluorochrome: Purified
Isotype: IgG1
Regulatory Status: RUO
Source Species: Mouse
Target Species: Chicken, Cow, Dog, Guinea pig, Horse, Human, Mouse, Non-Human Primates, Pig, Rabbit, Rat
Product number: CM881146

For Research Use Only

$120.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Concentration Unit mg/mL Concentration 1 Quantity 0.1 mg Volume 0.1 mL... more
Close menu
CyFlow™ CD79a Purified
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1 mL
ImmunogenSynthetic peptide corresponding to C terminal amino acids 208-222 of human CD79a
Background InformationCD79a (Ig α, MB1) forms disulfide-linked heterodimer with CD79b (Ig β, B29). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with λ5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. At the plasma cell stage, CD79a is present as an intracellular component. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Mason DY, Cordell JL, Tse AG, van Dongen JJ, van Noesel CJ, Micklem K, Pulford KA, Valensi F, Comans-Bitter WM, Borst J, et al: The IgM‑associated protein mb‑1 as a marker of normal and neoplastic B cells. J Immunol. 1991 Dec 1; 147(11):2474‑82. < PMID: 1747162 > | Rassenti LZ, Kipps TJ: Expression of Ig‑beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy‑chain allelic exclusion. Blood. 2000 Apr 15; 95(8):2725‑7. < PMID: 10753858 > | Torlakovic E, Torlakovic G: B‑cell markers in lymphocyte predominance Hodgkin disease. Arch Pathol Lab Med. 2002 Jul; 126(7):862‑3. < PMID: 12123231 > | Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, Melkus MW, Cravens PD, Martin Mdel P, Netto G, Garcia JV: Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein‑Barr virus. J Virol. 2004 Dec; 78(24):13891‑900. < PMID: 15564497 > | Fernandez NJ, West KH, Jackson ML, Kidney BA: Immunohistochemical and histochemical stains for differentiating canine cutaneous round cell tumors.. Vet Pathol. 2005 Jul; 42(4):437‑45. < PMID: 16006603 > | Bhargava P, Kallakury BV, Ross JS, Azumi N, Bagg A: CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone‑dependent manner. Am J Clin Pathol. 2007 Aug; 128(2):306‑13. < PMID: 17638667 > | Zhao XF, Hassan A, Perry A, Ning Y, Stass SA, Dehner LP: C‑MYC rearrangements are frequent in aggressive mature B‑Cell lymphoma with atypical morphology. Int J Clin Exp Pathol. 2008 Jan 1; 1(1):65‑74. < PMID: 18784824 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet